|
gptkbp:instanceOf
|
DrugBank identifier
|
|
gptkbp:affiliatedWith
|
gptkb:glucocorticoids
corticosteroids
|
|
gptkbp:approvalYear
|
1958
|
|
gptkbp:approvedBy
|
gptkb:FDA
|
|
gptkbp:ATCCode
|
gptkb:H02AB02
|
|
gptkbp:CASNumber
|
gptkb:50-02-2
|
|
gptkbp:contraindication
|
systemic fungal infections
|
|
gptkbp:discoveredBy
|
gptkb:Philip_Showalter_Hench
|
|
gptkbp:eliminationHalfLife
|
36-54 hours
|
|
gptkbp:excretion
|
urine
|
|
gptkbp:hasMolecularFormula
|
C22H29FO5
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
D00427
|
|
gptkbp:isAnti-inflammatory
|
true
|
|
gptkbp:isCorticosteroid
|
true
|
|
gptkbp:isGlucocorticoid
|
true
|
|
gptkbp:isImmunosuppressant
|
true
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:metabolism
|
liver
|
|
gptkbp:molecularWeight
|
392.461 g/mol
|
|
gptkbp:pregnancyCategory
|
C (US)
|
|
gptkbp:PubChem_CID
|
gptkb:CHEMBL384
gptkb:DB01234
5743
|
|
gptkbp:refersTo
|
gptkb:Dexamethasone
|
|
gptkbp:routeOfAdministration
|
oral
topical
intramuscular
intravenous
ophthalmic
|
|
gptkbp:sideEffect
|
gptkb:bone
hypertension
mood changes
weight gain
insomnia
increased appetite
hyperglycemia
adrenal suppression
|
|
gptkbp:synonym
|
gptkb:Ozurdex
gptkb:Decadron
gptkb:Maxidex
Dexamethasone acetate
Dexamethasone palmitate
Dexamethasone sodium phosphate
Hexadrol
|
|
gptkbp:UNII
|
7S5I7G3JQL
|
|
gptkbp:usedFor
|
gptkb:COVID-19
ulcerative colitis
arthritis
psoriasis
lupus
skin conditions
allergic disorders
breathing disorders
|
|
gptkbp:bfsParent
|
gptkb:Norvir
gptkb:ranitidine
|
|
gptkbp:bfsLayer
|
7
|